TOP > 外国特許検索 > DRUG-CARRYING HYDROGEL FORMULATION AND METHOD FOR PRODUCING SAME

DRUG-CARRYING HYDROGEL FORMULATION AND METHOD FOR PRODUCING SAME

外国特許コード F160008914
整理番号 (S2015-0921-N0)
掲載日 2016年12月21日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP059515
国際公開番号 WO 2016158707
国際出願日 平成28年3月24日(2016.3.24)
国際公開日 平成28年10月6日(2016.10.6)
優先権データ
  • 特願2015-073019 (2015.3.31) JP
発明の名称 (英語) DRUG-CARRYING HYDROGEL FORMULATION AND METHOD FOR PRODUCING SAME
発明の概要(英語) Provided are a drug-carrying formulation with which it is possible to carry out release with little initial burst, and a method for producing the same. Provided is a method for producing a drug-carrying hydrogel formulation, the method including the following: (a) a step for obtaining a biodegradable polymer gel by crosslinking a biodegradable polymer in an aqueous solution; (b) a step for finely granulating the biodegradable polymer gel; and (c) a step for obtaining a drug-carrying hydrogel by bringing the finely granulated biodegradable polymer gel into contact with a solution that contains a drug.
従来技術、競合技術の概要(英語) BACKGROUND ART
Peritoneal seeding, advanced gastric cancer and colorectal cancer and the like, cancer cells can be exposed to the serosal surface of the organ, and strewn (seeded) into the abdominal cavity, the peritoneum attached, lesion formation in the disease occurs. And seeding cancer cells into the abdominal cavity once, the total excision of the lesion difficult, often outside the adaptive surgery. Therefore, intravenous administration of the anticancer drug at present, such as oral administration and systemic chemotherapy is a standard of care, satisfactory effect is not obtained.
A peritoneal-seeding porosity may be poor blood flow, as systemic chemotherapy, intravenously, orally administered anticancer agent is difficult to bundle the routine proceeds to a peritoneal-seeding. In addition, systemic chemotherapy is, the more intense side effects associated with high blood levels. Many of the patients with peritoneal seeding already deteriorated general condition, from the viewpoint of QOL is impossible to effect in systemic chemotherapy is not small.
Of the anticancer drug into the blood concentration is associated with side effects since, while suppressing the blood concentration of the anti-cancer, anti-cancer lesions in the appropriate concentration of peritoneal-seeding for exposure, direct administration into the abdominal cavity anti-attempts have been made so far. However, such as gastric cancer and the effect of the water-soluble anticancer agent is cisplatin and the like, absorbs the earlier from the peritoneum, intraperitoneal administration, in order to obtain sufficient results have not yet been accomplished. Therefore, a biodegradable polymer such as gelatin in a state in which the anticancer drug is bound to the, intraperitoneally administered, sustained release anti-cancer therapeutic effect can be promoted, and by maintaining the appropriate blood concentration to reduce the side effects that the treatment method are now under study, animal studies have also been carried out (for example non-patent document 1).
Conventional, agent impregnated with the hydrogel formulation is a biodegradable polymer, referred to as initial burst upon administration and release of the agent, the ratio of the agent impregnated in the free from the split 3 reach about 2. For this reason, there is a loss of the drug, in addition to the cost for the preparation of the formulation, administration of the formulation of the subject person is exposed to high concentrations of medication which is problematic. In addition, a biodegradable polymer hydrogel formulations may be administered to a human for those that are, in their preparation, in many cases, an organic solvent such as acetone or hexane is used, prepared without using an organic solvent is desirable.
Therefore, less of the initial burst of the drug-carrying agent formulation, and, such formulations can be manufactured without using an organic solvent has been needed is a method.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • TSUNODA SHIGERU
  • SAKAI YOSHIHARU
  • TABATA YASUHIKO
  • GUNJI SHUTARO
  • YAMASHITA KOTA
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close